

**The effect of antidiabetic medications on non-alcoholic fatty liver disease
(NAFLD)**

Laura Iogna Prat, Emmanuel A. Tsochatzis

UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL,
London, UK

Key words: steatohepatitis, metformin, liraglutide, pioglitazone, HCC

FUNDING STATEMENT

No funding.

DECLARATION OF INTEREST

The authors declare that there is no conflict of interest

The term non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of liver disease ranging from steatosis (NAFL) to non alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. The diagnosis of NAFLD relies on imaging ¹ and histology which enables to distinguish simple fatty liver from NASH, where lobular inflammation and ballooning degeneration are also present ^{2,3}. This distinction is not a merely didactic classification but delines different outcomes: notably NAFL, due to its slower progression, is considered to have a benign course whereas NASH is strongly associated with the risk of developing liver fibrosis including cirrhosis and its complications ⁴⁻⁶. Moreover, in patients with NAFLD the severity of fibrosis is the strongest predictor of liver-related outcomes ^{7,8}.

NAFLD is at present the most common liver disorder in Western countries affecting about 25% of the population worldwide ⁹⁻¹¹; its prevalence ranges from 6% to 35% depending on different population groups, age and diagnostic techniques; furthermore, NAFLD is the second cause for liver transplantation in the USA and is projected to become the leading indication for liver transplant in the next 10 years ¹².

This epidemics coincides with the huge spread of obesity, type 2 diabetes (T2DM) and the metabolic syndrome (MS) in Western countries; accordingly, NAFLD is considered the hepatic manifestation of the latter ¹³. MS is a cluster of different components sharing insulin resistance as the common

pathophysiological feature ¹⁴: several studies demonstrated that MS is an independent predictor of development of NAFLD and NASH and its individual histological features including fibrosis ¹⁵⁻²⁰; notably, the more components of MS affecting a patient, the more frequently NAFLD will develop ²¹. However, NAFLD per se is also associated with a higher incidence of MS ²².

Although strong evidence supports the link between NAFLD and metabolic syndrome, in some cases, fatty liver can develop independently from MS, particularly in the presence of genetic variants of PNPLA 3 ²³.

On this basis, many studies had focused on the relationship between NAFLD and diabetes, supporting with growing evidence a bidirectional causative link and identifying insulin resistance as the key factor of this connection ^{24,25}.

At present there is no approved therapy for NASH. Until now, the only proven effective interventions in improving biochemical and histological features of NASH, including fibrosis, are weight loss ²⁶⁻²⁸ and physical activity even without weight loss ²⁹⁻³¹. Because of the common epidemiological and pathophysiological features between NAFLD and T2DM, many antidiabetics drugs have been tested in patients with NAFLD over the years. The rational and results of these studies are discussed in the present review.

Metformin

Metformin is an insulin sensitizer which has a multiorgan effect resulting in a decrease in plasma glucose and free fatty acids (FFA); in particular it reduces hepatic glucose production through suppression of gluconeogenesis and increased oxidation of fatty acids, inhibits lipolysis and subsequent FFA release from the adipose tissue, enhances glucose uptake and storage from the muscle and reduces intestinal glucose absorption ³². It is the preferred initial pharmacologic agent for the treatment of T2DM according to American and European guidelines ^{33,34}.

In a pilot study run in 2001 that included 20 non-diabetic patients, a 4 month course of metformin was associated with an improvement in serum aminotransferase levels, insulin sensitivity and liver volume detected with ultrasound (US) in patients with NAFLD. The study included patients with fatty liver and ALT increase ³⁵. This study, as others which followed using larger number of patients, longer treatment and histological outcomes, failed to show a superiority of metformin over diet interventions and lifestyle changes ³⁶⁻³⁹.

A positive effect on transaminases was observed in a larger study with 110 non-diabetic NAFLD patients receiving nutritional counseling at baseline, metformin was compared to vitamin E and dietetic intervention alone: aminotransferase levels improved in all groups, in association with weight loss, but the effects in the metformin group were more pronounced ⁴⁰. A subgroup of 17 metformin-treated patients with histological diagnosis of NASH at baseline (the majority of whom did not meet the primary outcome of normalization of ALT levels after 1 year treatment with metformin), underwent a post-treatment biopsy with

evidence of significant histological improvement in terms of steatosis, necroinflammation and fibrosis.

Furthermore, metformin was studied in combination with rosiglitazone in a randomized clinical trial (RCT) involving 137 patients with biopsy-proven NASH. Among the 108 subjects who completed the trial, 18 were diabetic. Subjects were divided into three groups receiving respectively rosiglitazone and metformin, rosiglitazone and losartan or rosiglitazone alone for 48 weeks. The primary outcome was improvement in steatosis, hepatocellular inflammation or fibrosis; no significant difference was found between the three treatment groups even if the within-group comparison showed a significant histological improvement of each component of NASH within all treatment arms ⁴¹.

Failure of metformin to significantly improve histological features in NASH was also confirmed in children and adolescents. The TONIC trial enrolled 173 non-diabetic patients aged 8-17 years old with biopsy-proven NAFLD and persistent increase in ALT. Patients were randomized to a 96-week course of metformin versus vitamin E versus placebo and the primary outcome was ALT decrease, while histological improvement/NASH resolution was the secondary outcome; neither vitamin E nor metformin was superior to placebo in achieving the primary outcome whereas the resolution of NASH was significantly greater in the vitamin E group; metformin, apart from an isolated improvement of ballooning degeneration, did not significantly resolve NASH ⁴².

Interestingly, although there is no benefit of using metformin to treat NAFLD, metformin seems to be effective on NAFLD-related complications: dose-

dependent reduction in hepatocellular carcinoma (HCC) was demonstrated in a large cohort of diabetic taiwanese patients ^{43,44} with a 7% reduction in the risk of HCC per year of metformin use. Furthermore, from a cardiovascular point of view, metformin is known to reduce cardiovascular complications related to diabetes ⁴⁵ and therefore may contribute to reduce such complications among NAFLD patients who are more prone to develop coronary, cerebrovascular and peripheral vascular disease independently of multiple CVD risk factors ⁴⁶.

Peroxisome proliferator-activated receptor agonists

Thiazolidinediones are peroxisome proliferator-activated receptor γ (PPAR- γ) agonists and act as insulin sensitizers on the muscle, adipose tissue and the liver. PPAR are a family of nuclear transcription factors divided in different subtypes (PPAR α , γ and β/δ) which have a large variety of effects on energy homeostasis and metabolism regulation. Compared to metformin, thiazolidinediones act more on peripheral tissues (adipose tissue, muscle) than on the liver due to the specific distribution of their target receptors ⁴⁷.

Rosiglitazone and pioglitazone, have been largely studied in NAFLD patients, however rosiglitazone was withdrawn from the European market in 2010 because of a high risk of myocardial infarction ⁴⁸. Regarding rosiglitazone, RCTs demonstrated a biochemical improvement on liver enzymes and glycaemic control both in diabetic and non-diabetic patients with NAFLD, whereas

evidence on histological improvement is less clear: results yielded from different studies are controversial regarding the effect on steatosis, ballooning and fibrosis⁴⁹⁻⁵²

In a single arm, open label trial involving 22 overweight/obese patients with biopsy-proven NASH, 15 of them with impaired glucose metabolism, a 48 week course of rosiglitazone improved significantly the mean global necroinflammatory score, steatosis, hepatocellular ballooning and fibrosis⁴⁹. Different results were obtained from other two single centre trials. In a cohort of 74 patients with biopsy-proven NASH a 48 week treatment with rosiglitazone associated to diet and physical activity, compared to diet and exercise alone, showed to significantly ameliorate NAS, steatosis and ballooning but no effect was detected on fibrosis⁵¹. Another study involved 64 patients with impaired glucose metabolism and biopsy-proven NAFLD who were randomly assigned to receive metformin or rosiglitazone or metformin plus rosiglitazone for 12 months. A control liver biopsy at the end of treatment was performed in 35 patients: NAS improvement was shown only in the groups receiving rosiglitazone but still no significant effect on fibrosis was detected⁵⁰.

Moreover, in the FLIRT trial, 63 patients with biopsy-proven NASH and increased ALT, of which 20 were diabetic, were randomized to receive either rosiglitazone or placebo for 1 year. The rosiglitazone group met the primary outcome of significant improvement/resolution of steatosis whereas no significant change was detected on any other histological lesions⁵². Subsequently 44 out of the original 63 patients participated in the extension phase of this study (FLIRT 2)

and were treated with rosiglitazone for two additional years. Interestingly, after this further treatment, significant improvement in steatosis was seen only in patients treated with placebo during the FLIRT whereas patients who already received rosiglitazone during the FLIRT showed no additional benefit with longer duration of treatment ⁵³. Combination treatment with metformin does not confer additional benefits apart from a part mitigation of weight gain due to rosiglitazone ⁴¹.

Pioglitazone was also broadly evaluated in clinical trials. A prospective pilot study ran in 2004 involved 18 non-diabetic patients with biopsy-proven NASH and tested hepatic histological improvement as primary outcome after 48 week course of pioglitazone: results showed significant improvement in histology regarding all main features of NASH (steatosis, parenchymal inflammation, cellular injury and Mallory bodies) including fibrosis despite a significant increase in body weight ⁵⁴. Follow up after 48 weeks of the end of treatment revealed a significant recurrence of NASH in those who had previously recovered with serum transaminase and histology similar to the baseline ⁵⁵ suggesting a need for a lifelong therapy duration. Interestingly, there was no worsening of fibrosis in these patients.

Promising results of the efficacy of pioglitazone among NAFLD diabetic patients has been demonstrated in a RCT of pioglitazone versus placebo involving 55 subjects, which showed a significant histological improvement of steatosis, inflammation and ballooning and reduction in liver fat content (assessed by magnetic resonance spectroscopy) after treatment ⁵⁶. In this study no effect of

pioglitazone on liver fibrosis was shown.

A subsequent double blind RCT conducted in 2008 that included 74 non-diabetic patients with NAFLD confirmed the beneficial effects of pioglitazone on liver histology. The primary outcome was the reduction in hepatocyte injury (namely cellular ballooning, apoptosis and necrosis) and fibrosis score. Pioglitazone was tested versus placebo and showed a significant improvement not only in steatosis but also in hepatocyte injury, lobular inflammation, Mallory bodies and fibrosis ⁵⁷.

Compared to these studies, contrasting results have been collected from a big multicentre phase III RCT (the PIVENS trial) which involved 247 non-diabetic patients with biopsy-proven NASH and compared vitamin E versus pioglitazone versus placebo after 96 week-treatment. In this trial only vitamin E met the prespecified significance level of the primary outcome (ie improvement in histological findings which included an improvement in hepatocellular ballooning) although both active-treatment groups had a significant reduction in steatosis, lobular inflammation and NAS (NAFLD activity score). This results was explained by the authors by the lack of hepatocellular ballooning in a more consistent percentage of subjects within the pioglitazone group on initial biopsies as assessed after central review. In fact, when subjects who initially did not have hepatocellular ballooning were excluded from the analyses, both active drug groups were associated with a significant improvement in histological findings. Neither vitamin E nor pioglitazone improved significantly fibrosis score in this study ⁵⁸.

More recently Cusi et al. ran a similar RCT involving 101 prediabetic and diabetic patients with biopsy-proven NASH who were randomized to receive pioglitazone or placebo for 18 months. The pioglitazone group, compared to placebo, showed a significant improvement of NAS and no worsening of fibrosis (primary outcome). Moreover, in the pioglitazone group there was a significant resolution of NASH, significant improvement in all the single main features of NASH (steatosis, inflammation and ballooning necrosis) and significant reduction in the fibrosis score. Extending treatment with pioglitazone for further 18 months gave no additional benefit ⁵⁹.

A metaanalysis of thiazolidinediones supported the beneficial effects of pioglitazone on liver fibrosis. It included 8 RCTs (5 evaluating pioglitazone and 3 evaluating rosiglitazone) enrolling 516 patients with biopsy-proven NASH for a duration of 6 to 24 months. Thiazolidinedione therapy was associated with improving advanced fibrosis (OR 3.15, 95% CI, 1.25-7.93), fibrosis of any stage (OR 1.66, 95% CI, 1.12-2.47) and NASH resolution (OR 3.22, 95% CI, 2.17-4.79). Similar results were obtained restricting analyses to RCTs enrolling non-diabetic patients. Beneficial effects were accounted for by pioglitazone use whereas rosiglitazone use did not reach statistical significance for any histological outcome ⁶⁰.

It is important to underscore that pioglitazone is associated with potentially serious adverse events such as fluid retention, weight gain and increased risk of congestive heart failure even in the absence of increased cardiovascular mortality ^{61,62} Notably, weight gain seems to persist even after discontinuation

of the drug ⁵⁵.

Regarding other PPAR agonists, research is currently focusing on the development of new molecules for the treatment of NAFLD. Saroglitazar, a dual PPAR α/γ agonist currently used in India for treatment of diabetic dyslipidaemia, has shown promising effects in experimental models of NASH ⁶³ and seems to be effective also in humans reducing serum aminotransferase levels and liver size assessed by US in NASH patients after a 24 week course ⁶⁴; a small phase IIa single arm clinical trial (PRESS VIII) using saroglitazar in biopsy-proven NASH patients has finished recruitment and its results are awaited. In contrast with pioglitazone, saroglitazar does not seem to correlate with weight gain and peripheral edema ⁶⁵.

Other than saroglitazar, elafibranor, a PPAR α/δ agonist, was tested in a 1-year phase II RCT involving 274 subjects with biopsy-proven NASH, 107 of which were diabetic: using a modified post-hoc primary endpoint, elafibranor resolved NASH in a significant percentage of patients without worsening of fibrosis and ameliorated the hepatic and metabolic profile ⁶⁶. In this large study no cardiovascular events or deaths in the elafibranor arm were reported. Currently, a phase III RCT evaluating histological improvement, all-cause mortality and liver-related outcomes in patients with NASH and fibrosis is ongoing. (ClinicalTrials.gov Identifier: NCT02704403).

Lobeglitazone, a PPAR α/γ agonist licensed in Korea for treatment of T2DM, has been recently studied in a pilot trial recruiting diabetic NASH patients diagnosed by CAP values on Fibroscan; this drug was shown to reduce CAP values

independently of glucose lowering effect, improve lipid, glycemic and hepatic serum parameters ⁶⁷.

Glucagon-like peptide 1 receptor (GLP- 1 R) agonists

This class of drugs (which includes liraglutide, exenatide, lixisenatide and dulaglutide), acts on the pancreas, brain and adipose tissue in a way similar to physiological GLP 1 and exert its antidiabetic effect through controlling food intake, energy absorption and glucose-dependent insulin secretion ⁶⁸. They are considered a second-line treatment for T2DM ³³. Apart from their glucose lowering effect, they have further positive consequences such as cardio-protective effects ^{69,70} and an induction of weight loss which is very beneficial in patients with NAFLD ⁷¹.

In a metanalysis including 4442 patients, liraglutide improved serum transaminases in diabetic patients; this effect is thought to be mediated by its action on weight loss and improved glycaemic control ⁷².

Moreover, apart from the presence or absence of NAFLD, liraglutide reduced liver fat content as assessed by MRI spectroscopy in patients with uncontrolled T2DM thanks to its weight lowering effect, whereas insulin glargine, despite an effective control on glycaemic status, exerted no improvement on weight loss and liver fat content ⁷³. However, these results have been in contrast with those obtained by Tang who compared the effect of a 12-week course of insulin

glargine versus liraglutide among 35 patients with T2DM inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic drugs. Despite similar glycaemic control, the insulin group showed significant reduction in liver fat burden assessed radiologically (mean MRI-PDFF, liver volume, total liver fat index) whereas no significant change was detected in the liraglutide group ⁷⁴. In agreement with the results of Tang, no changes in liver fat content and surrogate biomarkers of fibrosis were shown in a RCT comparing the effect of 12 week course with liraglutide versus sitagliptin or placebo among 52 overweight diabetic patients on metformin or sulphonylurea. Results did not change restricting the analysis to patients with NAFLD at baseline (15 patients in the liraglutide group, 16 in the sitagliptin group and 15 in the placebo group) ⁷⁵.

Histological effects of liraglutide have been recently studied in a pilot phase II multicentre RCT involving 52 patients with biopsy-proven NASH, 17 of which had T2DM; liraglutide met the primary endpoint of NASH resolution without worsening of fibrosis both in diabetic and non diabetic patients. These results were attributed in part to a cumulative effect on weight loss and glycaemic control ⁷⁶. In this trial, a subgroup of patients was assessed for organ specific insulin sensitivity, hepatic lipid handling and adipose dysfunction: the results showed that liraglutide improved hepatic and adipose insulin sensitivity and reduced the hepatic de novo lipogenesis ⁷⁷, a key component of the hepatic fat accumulation in NASH.

Evidence of an hepatoprotective effect also exists for exenatide: this drug has

been evaluated in several randomized clinical studies involving T2DM and obese patients and was shown to reduce liver enzymes, hepatic fat content, hepatic triglyceride content and epicardial fat ⁷⁸⁻⁸⁰. Similar to other GLP-1R agonists, results were influenced by the simultaneous weight loss observed in these studies. Histological efficacy of exenatide was investigated in 8 diabetic patients with biopsy proven NAFLD but, although some improvement in isolated histologic features and fibrosis was demonstrated, there was no statistical significance, most likely due to the small sample size ⁸¹.

Impact of lixisenatide and dulaglutide on NAFLD is not well known by now as few studies have been completed ^{82,83}.

Another GLP-1 agonist, semaglutide, is in development for the treatment of T2DM. An ongoing phase IIb RCT, currently recruiting patients, aims to evaluate the safety and efficacy of this drug in NASH with a primary outcome consisting in NASH resolution without worsening of fibrosis. The trial, which has a duration of 72 weeks, is planned to finish in July 2019 (ClinicalTrials.gov Identifier: NCT02970942).

The vast majority of these studies highlighted frequent gastrointestinal side effects from GPL-1 RA, however these usually subside after the initial phase of dose escalation (usually 6 weeks).

Dipeptidil dipeptidase-4 inhibitors

These drugs, consisting primarily of sitagliptin, vildagliptin, linagliptin, saxagliptin, and alogliptin, enhance the effects of incretins by inhibiting dipeptidil dipeptidase 4 (DPP-4), the enzyme responsible for their degradation. Incretins are a group of metabolic hormones released from the bowel in response to a meal. The main molecules of this group, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP), exert a common glucoregulatory effect stimulating insulin biosynthesis, β -cell proliferation and glucose-dependent insulin secretion from pancreas: furthermore, they exert different multiorgan effects. In particular GLP-1 acts on the stomach slowing gastric emptying and, indirectly, enhances glucose uptake from the muscle and adipose tissue. Because native incretins have a very short half-life, degradation resistant GLP-1R agonist and inhibitors of DPP-4 have been developed as antidiabetic medications ⁶⁸.

DPP-4 inhibitors are neutral on body weight and on cardiovascular system according to major cardiovascular events rates even if the rate of hospitalization due to heart failure was increased for saxagliptin ⁸⁴⁻⁸⁶.

In animal models of NASH, DPP-4 inhibitors showed promising results preventing the development of steatohepatitis by affecting both inflammatory and fibrosis pathways; this effect seems to be due to different mechanisms

including reduced expression of proinflammatory mediators such as TNF α , IL-6 and p-NFkB, attenuation of endoplasmic reticulum stress, reduction in hepatocyte apoptosis, decreased accumulation of fibronectin and alpha-smooth muscle actin (α -SMA) and reduction in plasminogen activator inhibitor 1 (PAI-1) expression ^{87,88}. Nevertheless in humans, the efficacy of DPP-4 inhibitors on NAFLD was more difficult to prove and results yielded by now are conflicting.

Although a small observational pilot study on 15 diabetic patients with biopsy-proven NAFLD demonstrated biochemical and histological improvement after 1 year course of sitagliptin ⁸⁹, further RCTs failed to demonstrate any beneficial effect of sitagliptin on NAFLD in diabetic patients. Limitations of these studies are the small number of patients involved, the relatively short duration of intervention (6 months) and the lack of evaluated histological outcomes ^{90,91}.

Furthermore, in a 24-week RCT involving 52 overweight patients with T2DM, sitagliptin was compared with liraglutide and placebo according to the study endpoints of evaluation of hepatic fat content and hepatic fibrosis: no difference in hepatic fat content measured with H-MRS and surrogate indicators of liver fibrosis was shown between the 3 groups ⁷⁵.

On the other side, a Japanese single-centre open-label trial compared sitagliptin at suboptimal dosage with glimepiride in a cohort of 20 diabetic patients with ultrasound evidence of fatty liver: after 24 weeks of treatment, in the sitagliptin group but not in the glimepiride group there was a significant reduction in intrahepatic lipid content and total body fat mass on H-MRS and DEXA despite similar decrease in HbA1c ⁹².

There are even less studies supporting the effect of other types of DPP-4 in NAFLD: in a double blind RCT involving 44 patients with well controlled T2DM vildagliptin was proved to reduce liver trygliceride content assessed by MRI along with a significant improvement in serum transaminase and fasting plasma glucose after a 6 month course ⁹³; for alogliptin evidence of any effects in NAFLD are poor ⁹⁴.

Further evidence supporting the efficacy of this class of drugs are awaited from two similar ongoing phase III clinical trials: NCT02147925 aimed to compare the change of intrahepatic lipids (IHL) in type 2 diabetic patients with non-alcoholic fatty-liver disease after a 26-week treatment of liraglutide, sitagliptin or insulin glargine per day combined with metformin whereas NCT02365233 asses similar outcome comparing pioglitazone to DPP-4 inhibitors (sitagliptin or saxagliptin) to insulin glargine.

Sodium-glucose co-transporters (SGLT2) inhibitors

This class of antidiabetic drugs lowers plasma glucose by inhibiting glucose reabsorption in the renal proximal tubule. Their mechanism of action is independent from insulin secretion or action and is not affected by pancreatic β cell function, making them a suitable potential therapy at any stage of T2DM progression ⁹⁵.

Canaglifozin, dapaglifozin and empaglifozin are the active substances approved in Europe and United States as second line treatment in association with

metformin as well as third line treatment ³³. Other molecules, namely ipraglifozin, luseoglifozin and tofoglifozin, are approved only in Japan, while molecules such as ertuglifozin and sotaglifozin, are in clinical development.

Apart from their well-recognized efficacy in improving glycaemic profile in diabetic patients, SGLT2 inhibitors have shown numerous beneficial effects separate from glycaemic control which makes them a potentially useful therapy in the contest of NAFLD and its complications. In particular, they can induce weight loss by decreasing body fat mass and exert a cardiorenal protection by lowering blood pressure, arterial stiffness and renal hyperfiltration ⁹⁶. Notably, long terms effects of empaglifozin on renal and cardiovascular outcomes were assessed with the EMPA REG OUTCOME trial which demonstrated a reduction in the risk of of death from cardiovascular disease (HR 0.62, 95% CI, 0.49-0.77), hospitalization for heart failure (HR 0.65, 95% CI, 0.50-0.85) and death from any cause (HR 0.68, 95% CI, 0.57-0.82) ⁹⁷ as well as slower progression of kidney disease (HR 0.61, 95% CI, 0.53 to 0.70) and lower rates of clinically relevant renal events than placebo (HR 0.54, 95% CI, 0.40-0.75) ⁹⁸.

Based on the above evidence, SGLT2 inhibitors have been tested in numerous NAFLD animal models, showing promising results. In obese mice with diet induced NAFLD remoglifozin reduced plasma aminotransferase levels, liver weight and hepatic trygliceride content ⁹⁹. Empaglifozin was studied alone and in combination with linagliptin in a novel mouse model of NASH and diabetes showing antisteatotic and antiinflammatory effects in both cases while an antifibrotic effect was only demonstrated in combination with linagliptin ¹⁰⁰.

Benefits on liver steatosis in animal models exists also for others SGLT2 inhibitors such as luseoglifozin and ipraglifozin ^{101,102}.

Human studies assessing the efficacy of SGLT2 inhibitors for NAFLD are still scarce: there is some evidence that canaglifozin and dapaglifozin may lower serum aminotransferase in diabetic patients ^{103,104} but data on histological outcomes are lacking. Their side effects include increased risk of genital mycotic infections and urinary tract infections, diabetic ketoacidosis and bone fractures ⁹⁶. Due to their mechanism of action, which is independent from β cell function, SGLT2 inhibitors do not cause hypoglycemia. In February 2017 EMA issued a warning concerning increased risk of lower limb amputation (especially toes) related to SGLT2 inhibitor therapy although this risk was demonstrated to be significant only for canaglifozin ¹⁰⁵.

α glucosidase inhibitors

Acarbose and miglitol inhibit the intestinal enzyme α glucosidase which is responsible for the breakdown of complex carbohydrates into small monosaccharides and therefore slow intestinal carbohydrate digestion and absorption. Due to their only modest antidiabetic efficacy, the frequency of administration and their side effects, they are not often used into clinical practice ³³.

Despite some scientific interest for the use of acarbose for the treatment of NAFLD ¹⁰⁶ there is scarce data on the effect of this class of drugs in NAFLD animal models ^{107,108} and none in humans. Acarbose was occasionally associated with a mild symptomless increase in aminotransferase levels and even one case of acute hepatotoxicity ¹⁰⁹ which was however recognized as idiosyncratic reaction. Despite this, acarbose has been proved to be safe in patients with cirrhosis ¹¹⁰ and to reduce cardiovascular events and hypertension among patients with impaired glucose tolerance ¹¹¹.

Intensive insulin therapy

Although insulin resistance is one of the leading force for the development of NAFLD in most cases ⁴⁰ insulin therapy has not been proved to resolve or improve NAFLD. On the contrary, insulin therapy has been associated with weight gain and increased risk of cardiovascular events ^{112,113} which are common risk factors in patients diagnosed with NAFLD.

Conclusions

Despite the huge progress in the understanding of the natural history and the pathophysiology of NAFLD ¹¹⁴, effective therapeutic options are still lacking. Among the antidiabetic drugs, the evidence of potential efficacy is stronger for

pioglitazone; there are however important potential side effects, notably peripheral oedema resulting in weight gain, that need to be considered. Liraglutide is also promising, however further data are required. Other antidiabetic drugs such as DPP-4 inhibitors and SGLT2 inhibitors could be a promising option and further studies with histological outcomes are awaited^{115,116}.

According to the available evidence, it would be clinically useful to define a stepwise approach to antidiabetic treatment in patients with NAFLD. Metformin, as suggested from international guidelines, should be the first-line treatment: patients with NAFLD can benefit from its positive impact on body weight (trend to weight loss) and from a decrease in the risk of HCC which seems to occur even in absence of cirrhosis in those patients¹¹⁷. Second line treatment should be chosen according to the nutritional status of the patient (ie BMI): in obese patients (BMI>30-35 kg/m²) GLP-1 agonists could be an helpful option considering their positive effect on body weight and potential beneficial effect on histology, whereas in normal weight or overweight patients (BMI<30 kg/m²) use of pioglitazone can be justified even if it associated with weight increase.

In the next few years the scenario in the treatment of NAFLD is expected to change as big phase IIb and III trials with histological outcomes are running (ClinicalTrials.gov Identifier: NCT02970942 and NCT02704403); semaglutide and elafibranor may be effective not only on steatosis and inflammation but also on

fibrosis and thus be able to modify the strongest predictor of disease-specific mortality in patients with NAFLD.

- ¹ Festi D, Schiumerini R, Marasco G et al., 2015 Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. *Expert Rev Gastroenterol Hepatol* 9: 1039-1053.
- ² European association for the study of the liver, European association for the study of diabetes, and European association for the study of obesity, 2016 EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 64: 1388-1402.
- ³ Chalasani N, Younossi Z, Lavine JE et al., 2012 The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 142: 1592-1609.
- ⁴ McCullough AJ, 2006 Pathophysiology of Nonalcoholic Steatohepatitis. *J Clin Gastroenterol* 40: S17-S29.
- ⁵ Singh S, Allen AM, Wang Z et al., 2015 Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis

of paired-biopsy studies. Clin Gastroenterol Hepatol 13: 643-654.

⁶ Marengo A, Jouness RI, and Bugianesi E, 2016 Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clin Liver Dis 20: 313-324.

⁷ Angulo P, Kleiner DE, Dam-Larsen S et al., 2015 Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149: 389-397 e310.

⁸ Ekstedt M, Hagstrom H, Nasr P et al., 2015 Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61: 1547-1554.

⁹ Vernon G, Baranova A, and Younossi ZM, 2011 Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285.

¹⁰ Younossi ZM, Koenig AB, Abdelatif D et al., 2016 Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology 64: 73-84.

- 11 Bellentani S, 2017 The epidemiology of non-alcoholic fatty liver disease. *Liver Int* 37 Suppl 1: 81-84.
- 12 Wong RJ, Aguilar M, Cheung R et al., 2015 Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 148: 547-555.
- 13 McCullough AJ, 2011 Epidemiology of the metabolic syndrome in the USA. *J Dig Dis* 12: 333-340.
- 14 Alberti KG, Eckel RH, Grundy SM et al., 2009 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 120: 1640-1645.
- 15 Ryan MC, Wilson A, Slavin J et al., 2005 Associations Between Liver Histology and Severity of the Metabolic Syndrome in Subjects With Nonalcoholic Fatty Liver Disease. *Diabetes Care* 28: 1222-1224.
- 16 Hamaguchi M, Kojima T, Takeda N et al., 2005 The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. *Ann Intern Med* 143:722-728.

- 17 Marchesini G, Bugianesi E, Forlani G et al., 2003
Nonalcoholic fatty liver, steatohepatitis, and the
metabolic syndrome. *Hepatology* 37: 917-923.
- 18 Ballestri S, Nascimbeni F, Romagnoli D, and Lonardo A,
2016 The independent predictors of non-alcoholic
steatohepatitis and its individual histological features.:
Insulin resistance, serum uric acid, metabolic
syndrome, alanine aminotransferase and serum total
cholesterol are a clue to pathogenesis and candidate
targets for treatment. *Hepatol Res* 46: 1074-1087.
- 19 Tsochatzis E, Papatheodoridis GV, Manesis EK et al.,
2008 Metabolic syndrome is associated with severe
fibrosis in chronic viral hepatitis and non-alcoholic
steatohepatitis. *Aliment Pharmacol Ther* 27: 80-89.
- 20 Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV,
and Archimandritis AJ, 2009 Insulin resistance and
metabolic syndrome in chronic liver diseases: old
entities with new implications. *Scand J Gastroenterol*
44: 6-14.
- 21 Petta S, Eslam M, Valenti L et al., 2017 Metabolic
syndrome and severity of fibrosis in nonalcoholic fatty
liver disease: An age-dependent risk profiling study.
Liver Int 37: 1389-1396.

- ²² Lonardo A, Ballestri S, Marchesini G, Angulo P, and Loria P, 2015 Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. *Dig Liver Dis* 47: 181-190.
- ²³ Shen J, Wong GL, Chan HL et al., 2014 PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. *Aliment Pharmacol Ther* 39: 532-539.
- ²⁴ Anstee QM, Targher G, and Day CP, 2013 Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 10: 330-344.
- ²⁵ Yki-Järvinen H, 2014 Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *The Lancet Diabetes & Endocrinology* 2: 901-910.
- ²⁶ Promrat K, Kleiner DE, Niemeier HM et al., 2010 Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 51: 121-129.
- ²⁷ Glass LM, Dickson RC, Anderson JC et al., 2015 Total body weight loss of $\geq 10\%$ is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. *Dig Dis Sci* 60: 1024-1030.

- 28 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al., 2015 Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology* 149: 367-378 e365; quiz e314-365.
- 29 Houghton D, Thoma C, Hallsworth K et al., 2017 Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. *Clin Gastroenterol Hepatol* 15: 96-102 e103.
- 30 Ratziu V, 2017 Non-pharmacological interventions in non-alcoholic fatty liver disease patients. *Liver Int* 37 Suppl 1: 90-96.
- 31 Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, and Kontogianni MD, 2017 Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. *Metabolism* 68: 119-132.
- 32 Foretz M, Guigas B, Bertrand L, Pollak M, and Viollet B, 2014 Metformin: from mechanisms of action to therapies. *Cell Metab* 20: 953-966.
- 33 American Diabetes Association, 2017 Standards of medical care in diabetes-2017. *Diabetes Care* 40.

- ³⁴ Inzucchi SE, Bergenstal RM, Buse JB et al., 2012 Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 55: 1577-1596.
- ³⁵ Marchesini G, Bianchi G, Tomassetti S, Zoli M, and Melchionda N, 2001 Metformin in non-alcoholic steatohepatitis. *The Lancet* 358: 893-894.
- ³⁶ Nair S, Diehl AM, Wiseman M, Farr GH, Jr., and Perrillo RP, 2004 Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. *Aliment Pharmacol Ther* 20: 23-28.
- ³⁷ Uygun A, Kadayifci A, Isik AT et al., 2004 Metformin in the treatment of patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 19: 537-544.
- ³⁸ Schields WW, Thompson KE, Grice GA, Harrison SA, and Coyle WJ, 2009 The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. *Therap Adv Gastroenterol* 2: 157-163.
- ³⁹ Loomba R, Lutchman G, Kleiner DE et al., 2009 Clinical trial: pilot study of metformin for the treatment of non-

alcoholic steatohepatitis. *Aliment Pharmacol Ther* 29: 172-182.

⁴⁰ Bugianesi E, Gentilcore E, Manini R et al., 2005 A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. *Am J Gastroenterol* 100: 1082-1090.

⁴¹ Torres DM, Jones FJ, Shaw JC et al., 2011 Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. *Hepatology* 54: 1631-1639.

⁴² Lavine JE, Schwimmer JB, Van Natta ML et al., 2011 Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents The TONIC Randomized Controlled Trial. *JAMA* 305: 1659-1668.

⁴³ Chen HP, Shieh JJ, Chang CC et al., 2013 Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. *Gut* 62: 606-615.

⁴⁴ Bhat A, Sebastiani G, and Bhat M, 2015 Systematic review: Preventive and therapeutic applications of

metformin in liver disease. *World J Hepatol* 7: 1652-1659.

45 Holman RR, Paul SK, Bethel MA, Matthews DR, and Neil HA, 2008 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 359: 1577-1589.

46 Targher G, Bertolini L, Padovani R et al., 2007 Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients. *Diabetes Care* 30: 1212-1218.

47 Grygiel-Górniak B, 2014 Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. *Nutrition Journal* 13:17.

48 Nissen SE and Wolski K, 2007 Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *N Engl J Med* 356: 2457-2471.

49 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, and Bacon BR, 2003 Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the PPAR- γ Ligand Rosiglitazone. *Hepatology* 38: 1008-1017.

50 Omer Z, Cetinkalp S, Akyildiz M et al., 2010 Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 22: 18-23.

- ⁵¹ Idilman R, Mizrak D, Corapcioglu D et al., 2008 Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 28: 200-208.
- ⁵² Ratziu V, Giral P, Jacqueminet S et al., 2008 Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. *Gastroenterology* 135: 100-110.
- ⁵³ Ratziu V, Charlotte F, Bernhardt C et al., 2010 Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. *Hepatology* 51: 445-453.
- ⁵⁴ Promrat K, Lutchman G, Uwaifo GI et al., 2004 A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. *Hepatology* 39: 188-196.
- ⁵⁵ Lutchman G, Modi A, Kleiner DE et al., 2007 The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. *Hepatology* 46: 424-429.
- ⁵⁶ Belfort R, Harrison SA, Brown K et al., 2006 A placebo-controlled trial of pioglitazone in subjects with

nonalcoholic steatohepatitis. *N Engl J Med* 355: 2297-2307.

⁵⁷ Aithal GP, Thomas JA, Kaye PV et al., 2008 Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology* 135: 1176-1184.

⁵⁸ Sanyal AJ, Chalasani N, Kowdley KW et al., 2010 Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. *N Engl J Med* 362: 1675-1685.

⁵⁹ Cusi K, Orsak B, Bril F et al., 2016 Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. *Ann Intern Med* 165: 305-315.

⁶⁰ Musso G, Cassader M, Paschetta E, and Gambino R, 2017 Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. *JAMA Intern Med* 177: 633-640.

⁶¹ Lincoff AM, Wolski K, Nicholls SJ, and Nissen SE, 2007 Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus A Meta-analysis of Randomized Trials. *JAMA* 298: 1180-1188.

⁶² Lago RM, Singh PP, and Nesto RW, 2007 Congestive heart failure and cardiovascular death in patients with

prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *The Lancet* 370: 1129-1136.

⁶³ Jain MR, Giri SR, Bhoi B et al., 75th Scientific Session - ADA, June 5-9, 2015 • Boston, MA, USA Saroglitazar Shows Therapeutic Benefits in Mouse Model of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). Poster.

⁶⁴ Jain MR, Giri SR, Trivedi C et al., 2015 Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. *Pharmacol Res Perspect* 3: e00136.

⁶⁵ Pai V, Paneerselvam A, Mukhopadhyay S et al., 2014 A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). *J Diabetes Sci Technol* 8: 132-141.

⁶⁶ Ratziu V, Harrison SA, Francque S et al., 2016 Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without

Fibrosis Worsening. *Gastroenterology* 150: 1147-1159
e1145.

⁶⁷ Lee YH, Kim JH, Kim SR et al., 2017 Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. *J Korean Med Sci* 32: 60-69.

⁶⁸ Baggio LL and Drucker DJ, 2007 Biology of incretins: GLP-1 and GIP. *Gastroenterology* 132: 2131-2157.

⁶⁹ Marso SP, Daniels GH, Brown-Frandsen K et al., 2016 Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 375: 311-322.

⁷⁰ Rizvi AA, Patti AM, Giglio RV et al., 2015 Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. *Expert Opin Biol Ther* 15: 1391-1397.

⁷¹ McAdam-Marx C, Nguyen H, Schauerhamer MB et al., 2016 Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis. *Clin Ther* 38: 2642-2651.

⁷² Armstrong MJ, Houlihan DD, Rowe IA et al., 2013 Safety and efficacy of liraglutide in patients with type 2

diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. *Aliment Pharmacol Ther* 37: 234-242.

- ⁷³ Petit JM, Cercueil JP, Loffroy R et al., 2017 Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. *J Clin Endocrinol Metab* 102: 407-415.
- ⁷⁴ Tang A, Rabasa-Lhoret R, Castel H et al., 2015 Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. *Diabetes Care* 38: 1339-1346.
- ⁷⁵ Smits MM, Tonneijck L, Muskiet MH et al., 2016 Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. *Diabetologia* 59: 2588-2593.
- ⁷⁶ Armstrong MJ, Gaunt P, Aithal GP et al., 2016 Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 387: 679-690.

- 77 Armstrong MJ, Hull D, Guo K et al., 2016 Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. *J Hepatol* 64: 399-408.
- 78 Sathyanarayana P, Jogi M, Muthupillai R et al., 2011 Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. *Obesity (Silver Spring)* 19: 2310-2315.
- 79 Shao N, Kuang HY, Hao M et al., 2014 Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. *Diabetes Metab Res Rev* 30: 521-529.
- 80 Dutour A, Abdesselam I, Ancel P et al., 2016 Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. *Diabetes Obes Metab* 18: 882-891.
- 81 Kenny PR, Brady DE, Torres DM et al., 2010 Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. *Am J Gastroenterol* 105: 2707-2709.
- 82 Gluud LL, Knop FK, and Vilsboll T, 2014 Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of

randomised controlled trials on patients with type 2 diabetes. *BMJ Open* 4: e005325.

⁸³ Seko Y, Sumida Y, Tanaka S et al., 2016 Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. *Hepatol Res* 47: 1206-1211.

⁸⁴ Green JB, Bethel MA, Armstrong PW et al., 2015 Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 373: 232-242.

⁸⁵ Scirica BM, Bhatt DL, Braunwald E et al., 2013 Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 369: 1317-1326.

⁸⁶ White WB, Cannon CP, Heller SR et al., 2013 Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* 369: 1327-1335.

⁸⁷ Shirakawa J, Fujii K, Ohnuma K et al., 2011 Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice. *Diabetes Metab Syndr* 60: 1246-1257.

⁸⁸ Jung YA, Choi YK, Jung GS et al., 2014 Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. *Diabetes Res Clin Pract* 105: 47-57.

- ⁸⁹ Yilmaz Y, Yonal O, Deyneli O et al., 2012 Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. *Acta Gastroenterol Belg.* 75: 240-244.
- ⁹⁰ Joy TR, McKenzie CA, Tirona RG et al., 2017 Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. *World J Gastroenterol* 23: 141-150.
- ⁹¹ Cui J, Philo L, Nguyen P et al., 2016 Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. *J Hepatol* 65: 369-376.
- ⁹² Kato H, Nagai Y, Ohta A et al., 2015 Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. *Diabetes Res Clin Pract* 109: 199-205.
- ⁹³ Macauley M, Hollingsworth KG, Smith FE et al., 2015 Effect of vildagliptin on hepatic steatosis. *J Clin Endocrinol Metab* 100: 1578-1585.
- ⁹⁴ Mashitani T, Noguchi R, Okura Y et al., 2016 Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. *Biomed Rep* 4: 183-187.
- ⁹⁵ Chao EC and Henry RR, 2010 SGLT2 inhibition--a novel strategy for diabetes treatment. *Nat Rev Drug Discov* 9: 551-559.

- ⁹⁶ Trujillo JM and Nuffer WA, 2017 Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. *Pharmacotherapy* 37: 481-491.
- ⁹⁷ Zinman B, Wanner C, Lachin JM et al., 2015 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 373: 2117-2128.
- ⁹⁸ Wanner C, Inzucchi SE, Lachin JM et al., 2016 Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med* 375: 323-334.
- ⁹⁹ Nakano S, Katsuno K, Isaji M et al., 2015 Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. *J Clin Exp Hepatol* 5: 190-198.
- ¹⁰⁰ Jojima T, Tomotsune T, Iijima T et al., 2016 Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. *Diabetol Metab Syndr* 8: 45.
- ¹⁰¹ Qiang S, Nakatsu Y, Seno Y et al., 2015 Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. *Diabetol Metab Syndr* 7: 104.

- 102 Komiya C, Tsuchiya K, Shiba K et al., 2016 Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One 11: e0151511.
- 103 Lavalle-Gonzalez FJ, Januszewicz A, Davidson J et al., 2013 Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56: 2582-2592.
- 104 Bailey CJ, Gross JL, Pieters A, Bastien A, and List JF, 2010 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.
- 105 Fadini GP and Avogaro A, 2017 SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. The Lancet Diabetes & Endocrinology 5: 680-681.
- 106 Yamagishi S, Nakamura K, and Inoue H, 2005 Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH). Med Hypotheses 65: 377-379.

- 107 Nozaki Y, Fujita K, Yoneda M et al., 2009 Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. *J Hepatol* 51: 548-556.
- 108 Rudovich NN WM, Machann J, Pfeiffer AFH, 2010 Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: A break of intestinal insulin resistance? *J Hepatol* 52: 951-954.
- 109 Carrascosa M, Pascual F, and Aresti S, 1997 Acarbose-induced acute severe hepatotoxicity. *The Lancet* 349: 698-699.
- 110 Gentile S TS, Guarino G et al. , 1999 Non-insulin-dependent diabetes mellitus associated with nonalcoholic livercirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose. *Ann Ital Med Int.* 14: 7-14.
- 111 Chiasson J JR, Gomis R, Hanefeld M, Karasik A, Laasko M, 2003 Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance. The STOP-NIDDMTrial. *JAMA* 290: 486-494.
- 112 Jil M, Rajnikant M, Richard D, and Iskandar I, 2017 The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2

diabetes: A retrospective cohort study. *Diab Vasc Dis Res* 14: 295-303.

113 Nystrom T, Bodegard J, Nathanson D et al., 2017
Second line initiation of insulin compared with DPP-4
inhibitors after metformin monotherapy is associated
with increased risk of all-cause mortality,
cardiovascular events, and severe hypoglycemia.
Diabetes Res Clin Pract 123: 199-208.

114 Buzzetti E, Pinzani M, and Tsochatzis EA, 2016 The
multiple-hit pathogenesis of non-alcoholic fatty liver
disease (NAFLD). *Metabolism* 65: 1038-1048.

115 Lazaridis N and Tsochatzis E, 2017 Current and future
treatment options in non-alcoholic steatohepatitis
(NASH). *Expert Rev Gastroenterol Hepatol* 11: 357-369.

116 Lombardi R, Onali S, Thorburn D et al., 2017
Pharmacological interventions for non-alcohol related
fatty liver disease (NAFLD): an attempted network
meta-analysis. *Cochrane Database Syst Rev* 3.

117 Wong CR, Nguyen MH, and Lim JK, 2016 Hepatocellular
carcinoma in patients with non-alcoholic fatty liver
disease. *World J Gastroenterol* 22: 8294-8303.

Table 1. Randomized controlled trials of antidiabetic medications in patients with biopsy-proven non-alcoholic steatohepatitis (NASH) that included more than 40 patients and used histology as the primary outcome

Author, year	Number of patients	T2DM	Intervention	Duration	Primary outcome	Result
Belfort, 2006 ⁵⁶	55	IGT /diabetics	Pioglitazone 45 mg vs placebo (1:1)	6 months	Improvement in histology, aminotransferase and metabolic parameters	Improvement in all main histological features except fibrosis
Aithal, 2008 ⁵⁷	74	Non diabetics	Pioglitazone 30 mg vs placebo (1:1)	12 months	Reduction in hepatocyte injury and fibrosis score on histology	Significant reduction in steatosis, hepatocellular injury (ballooning, apoptosis, MD bodies), and fibrosis in pioglitazone group
Sanyal, 2010 ⁵⁸	247	Non diabetics	Pioglitazone 30 mg vs vitamin E 800 IU vs. placebo (1:1:1)	96 weeks	Improvement in hepatocellular ballooning, no increase in fibrosis score, decrease of NAS score	Met the primary endpoint only in the vitamin E group
Cusi, 2016 ⁵⁹	101	Prediabetics and diabetics	Pioglitazone 45 mg vs. placebo 1:1	18 months	Reduction of NAS score in 2 histological categories and no worsening of fibrosis	Met the primary endpoint with significant resolution of NASH
Idilman, 2008 ⁵¹	74	Diabetics and non diabetics	Diet+exercise vs diet+exercise+insulinsensitizer (1:2)	48 weeks	Improvement in metabolic, biochemical and histological abnormalities	Met the primary endpoint
Ratziu, 2008 ⁵²	63	Diabetics and non diabetics	Rosiglitazone 8 mg vs placebo (1:1)	1 year	Reduction/disappearance of steatosis	Significant reduction/disappearance of steatosis in rosiglitazone group
Ratziu, 2010 ⁵³	44	Diabetics and non diabetics	Rosiglitazone 8 mg (extension phase of Ratziu 2008)	2 years	Reduction/disappearance of steatosis	Significant reduction/disappearance of steatosis only in patients treated with placebo in Ratziu 2008
Torres, 2011 ⁴¹	137	Diabetics and non diabetics	Rosiglitazone 8 mg vs rosiglitazone 8 mg+ metformin 1 g vs rosiglitazone 8 mg+ losartan 50 mg (1:1:1)	48 weeks	Improvement in steatosis, hepatocellular inflammation and fibrosis	No significant difference between groups
Armstrong, 2016 ⁷⁶	52	Diabetics and non diabetics	Liraglutide 1.8 mg vs placebo (1:1)	48 weeks	Resolution of NASH without worsening of fibrosis	Primary outcome met in both diabetics and non diabetics

T2DM: type 2 diabetes mellitus, IGT: impaired glucose tolerance, MD: Mallory-Denk, NAS: non alcoholic fatty liver disease activity score

